FDA warning on sale of unapproved stem cell product

5 January 2018
2019_biotech_test_vial_discovery_big

The US Food and Drug Administration (FDA) has issued a warning to American CryoStem Corporation (OTCMKTS: CRYO) for marketing an adipose derived stem cell product without FDA approval and for significant deviations from current Good Manufacturing Practice (GMP), including some that risk patient safety.

The New Jersey-based company calls itself a leading developer, manufacturer, and marketer of life-enhancing stem cell technologies in the field of personalized, regenerative medicine.

An FDA inspection found that it was receiving and processing adipose tissue into a product called Atcell and then marketing it without the required FDA approval.

This article is accessible to registered users, to continue reading please register for free.  A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Login to your account

Become a subscriber

 

£820

Or £77 per month

Subscribe Now
  • Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
  • Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
  • Daily roundup of key events in pharma and biotech.
  • Monthly in-depth briefings on Boardroom appointments and M&A news.
  • Choose from a cost-effective annual package or a flexible monthly subscription
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK



Today's issue

Company Spotlight





More Features in Biotechnology